Subscribe
cecilie_arcurs
cecilie_arcurs / iStockphoto.com
29 August 2017Americas

Gilead Sciences to acquire Kite Pharma for $11.9bn

Gilead Sciences is to acquire Kite Pharma for $11.9 billion, after the deal was unanimously approved by both companies’ boards of directors.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead follows Kite acquisition with $567m buy
12 December 2017   Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.
Americas
Pfizer and Allogene partner to develop cancer therapies
5 April 2018   Pfizer has revealed its plan to take a 25% stake in Allogene Therapeutics to further develop Pfizer’s allogeneic chimeric antigen receptor T cell (CAR T) therapy.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Gilead follows Kite acquisition with $567m buy
12 December 2017   Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.
Americas
Pfizer and Allogene partner to develop cancer therapies
5 April 2018   Pfizer has revealed its plan to take a 25% stake in Allogene Therapeutics to further develop Pfizer’s allogeneic chimeric antigen receptor T cell (CAR T) therapy.

More on this story

Americas
Gilead follows Kite acquisition with $567m buy
12 December 2017   Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.
Americas
Pfizer and Allogene partner to develop cancer therapies
5 April 2018   Pfizer has revealed its plan to take a 25% stake in Allogene Therapeutics to further develop Pfizer’s allogeneic chimeric antigen receptor T cell (CAR T) therapy.

More features

EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure